Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,300 papers from all fields of science
Search
Sign In
Create Free Account
American Society of Clinical Oncology
Known as:
ASCO
The world's leading professional organization representing physicians of all oncology disciplines and subspecialties. ASCO sets the standard for…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
Journal of Oncology Practice
2016
Corpus ID: 47571156
1. OVERVIEW: GENERAL PRINCIPLES FOR ALL ASCO GUIDELINE PRODUCTS ( e.g. de novo, Update, Endorsement, Adaptation, Provisional…
Expand
Highly Cited
2014
Highly Cited
2014
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from…
G. Minckwitz
,
E. Hahnen
,
+18 authors
Ago-B study groups
2014
Corpus ID: 78096251
1005 Background: We previously showed in participants with TNBC of the neoadjuvant phase II GeparSixto study (NCT01426880) that…
Expand
Highly Cited
2010
Highly Cited
2010
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma…
T. Conroy
,
F. Desseigne
,
+7 authors
A. Adenis
2010
Corpus ID: 70959416
4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate…
Expand
Highly Cited
2009
Highly Cited
2009
First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537).
C. Nutting
,
R. A’Hern
,
+7 authors
E. Hall
Journal of Clinical Oncology
2009
Corpus ID: 37619254
LBA6006 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings…
Expand
Review
2006
Review
2006
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
R. Motzer
,
Thomas E. Hutson
,
+7 authors
R. Figlin
Journal of Clinical Oncology
2006
Corpus ID: 23742297
LBA3 Background: Two multicenter phase II trials of 2nd line monotherapy with sunitinib (SU11248) in patients (pts) with mRCC…
Expand
Highly Cited
2005
Highly Cited
2005
Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance…
K. Kelly
,
L. Gaspar
,
K. Chansky
,
K. Albain
,
J. Crowley
,
D. Gandara
2005
Corpus ID: 74674245
7058 Background: Significant pneumonitis (≥ grade 3) is reported in up to 19% of patients (pts) with stage III non-small cell…
Expand
Highly Cited
2004
Highly Cited
2004
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
E. M. O 'reilly
,
G. Abou-Alfa
,
+7 authors
S. Eckhardt
Journal of Clinical Oncology
2004
Corpus ID: 21906610
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity…
Expand
2004
2004
Cancer prevention and the American Society of Clinical Oncology.
S. Lippman
,
B. Levin
,
+7 authors
M. Somerfield
Journal of Clinical Oncology
2004
Corpus ID: 30651184
Scott M. Lippman and Bernard Levin, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Dean E. Brenner…
Expand
Highly Cited
2004
Highly Cited
2004
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the…
A. Roth
,
R. Maibach
,
+7 authors
N. Fazio
Journal of Clinical Oncology
2004
Corpus ID: 42414688
4020 Background: ECF is currently considered by many as a standard regimen in AGC in Europe. Based on the high efficacy reported…
Expand
Review
1996
Review
1996
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
C. Bennett
,
T. Smith
,
+6 authors
R. Winn
Journal of Clinical Oncology
1996
Corpus ID: 24987436
PURPOSE Dissemination of use of the hematopoietic colony-stimulating factors (CSFs) is unprecedented in oncology, with almost all…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE